Praxis Precision Medicines Inc (NAS:PRAX)

$ 41.7 1.59 (3.96%) Market Cap: 713.40 Mil Enterprise Value: 508.21 Mil PE Ratio: 0 PB Ratio: 2.41 GF Score: 37/100

Praxis Precision Medicines Inc Extraordinary Shareholders Meeting Transcript
Nov 06, 2023
Praxis Precision Medicines Inc R&D Day Transcript
Oct 02, 2023
Praxis Precision Medicines Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2023
Praxis Precision Medicines Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 17, 2023
Praxis Precision Medicines Inc Essential1 Topline Results Call Transcript
Mar 03, 2023
Praxis Precision Medicines Inc at Citi Biopharma Co-Panel Day (Virtual) - Mood Disorders/Mental Health Panel Transcript
May 18, 2022
Praxis Precision Medicines Inc at Bank of America Healthcare Conference Transcript
May 11, 2022
Q1 2022 Praxis Precision Medicines Inc Earnings Call Transcript
May 09, 2022

$110.85 (-8.54%)

Earnings
Praxis Precision Medicines Inc Epilepsy Day Transcript
Apr 27, 2022
Praxis Precision Medicines Inc at Cowen Health Care Conference (Virtual) Transcript
Mar 07, 2022
Q4 2021 Praxis Precision Medicines Inc Earnings Call Transcript
Feb 28, 2022

$196.5 (-1.73%)

Earnings
Praxis Precision Medicines Inc Movement Disorder Day Transcript
Dec 17, 2021
Q3 2021 Praxis Precision Medicines Inc Earnings Call Transcript
Nov 03, 2021

$329.55 (+1.24%)

Earnings
Praxis Precision Medicines Inc at Citi BioPharma Conference (Virtual) Transcript
Sep 08, 2021
Praxis Precision Medicines Inc Annual Shareholders Meeting Transcript
Jun 08, 2021
Q4 2020 Praxis Precision Medicines Inc Earnings Call Transcript
Mar 17, 2021

$637.65 (+2.56%)

Earnings

Praxis Precision Medicines Inc Essential1 Topline Results Call Transcript

Mar 03, 2023 / 01:00PM GMT

Release Date Price: $14.95 (-65.87%)

Transcript

Operator

Good day, and thank you for standing by. Welcome to the Praxis Precision Medicine's Essential1 Top Line Results Call. (Operator Instructions) Please be advised that your conference is being recorded.

I would now like to hand the conference over to your speaker today, Alex Kane, Vice President, Investor Relations and Corporate Communications. Please go ahead.

Alex Kane

Praxis Precision Medicines, Inc. - VP of IR & Corporate Communications

Hi, everyone. Good day, and thank you for joining us. We are pleased to be with you today to discuss the top line results from the ulixacaltamide Phase IIb Essential1 study for the treatment of essential tremor. With me on today's call are President and Chief Executive Officer, Marcio Souza. We will be joined by additional members of the Praxis management team for a live Q&A session following today's prepared remarks.

Please note that today's remarks will reference the press release issued earlier this morning and the slide deck accessible through the Investors & Media section of our corporate

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.